Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
WALTHAM, Mass., Oct. 19, 2016 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its third quarter 2016 financial results will be released on Thursday, November 3, 2016 before the U.S. financial markets open. At 8:00 a.m. ET, management will host a conference call and webcast to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 96588865
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 96588865
A telephone replay will be available from approximately 11:00 a.m. ET on November 3, 2016 through midnight on November 10, 2016.
The webcast with slides will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
